antigens (p = 0-0008 and 0*005 respectively) in the neuropsychiatric group. The frequency of lymphocytotoxic autoantibodies was increased in neuropsychiatric patients with SLE having HLA-DR9 specificity (p = 0.04). how much the HLA marker contributes to disease at the population level, and preventive fraction (PF), which is an indicator of protection, were also estimated.'2
Results
The most frequent neuropsychiatric features were organic brain syndrome (33-3%), psychosis (30/9%), generalised seizures (30.9%), cranial neuropathies (28-6%), stroke (23-8%), peripheral neuropathies (19-1%; half associated with other disorders of the central nervous system and half isolated), aseptic meningitis (9-5%), pseudotumour cerebri (7 1%), and transverse myelitis (48-/8%). About 62% of patients presented neuropsychiatric manifestations considered to be of diffuse disease (organic brain syndrome, generalised seizures, psychosis), associated or not with focal disease, and 38% had only manifestations considered to be of focal disease (transverse myelitis, aseptic meningitis, pseudotumour cerebri, and cranial and peripheral neuropathies). Table 1 shows the additional clinical and laboratory features of the whole group of patients. Table 2 shows the frequencies of HLA class II antigens. Specificity for HLA-DR3 was significantly increased in the total group of patients with SLE (p = 0-003). Compared with controls, the patients with NPSLE also presented a significantly increased HLA-DR3 antigen (p=0-002; RR=3-03; EF=0-31). Compared with controls, HLA-DR4 specificity was overrepresented in patients with SLE without neuropsychiatric features (p = 0-00 1; RR = 3-16; EF =0-44) and underrepresented in patients with NPSLE (p = 0-0005; RR = 0-18; PF = 0-52). Comparisons of HLA class II frequency between patients with and without neuropsychiatric features showed an increased frequency of HIA-DR9 and HIA-DQ2 (p = 0-0008 and p = 0-005 respectively) and a decreased frequency of HLA-DR4 antigens (p < 0-00001) in patients with NPSLE. In patients with NPSLE, the comparisons between diffuse or focal disease with controls or with each other did not disclose significant differences in HLA antigen frequency.
Lymphocytotoxic autoantibodies were detected in 12 of 38 patients with NPSLE with involvement of the central nervous system and in only one of 20 randomly selected patients with non-neuropsychiatric SLE (p = 0-02). All controls were negative. Of the patients with lymphocytotoxic autoantibodies five were HLA-DR9 (all NPSLE), and eight were non-HLA-DR9 (seven NPSLE and one non-NPSLE). Therefore, the presence of lymphocytotoxic autoantibodies was positively associated with the presence of HLA-DR9 (p = 0-04). Only one patient had both lymphocytotoxic autoantibody and HLA-DQ2 antigen (p = 0-2). There were no associations between HIA antigens in NPSLE and other laboratory variables shown in table 1.
Compared with controls, the frequency of the combination of antigens HLA-DR3/DR4 was increased in non-NPSLE patients Silva, Donadi (p = 0 003) and HLA-DR3/DR9 was increased in patients with NPSLE (p = 0-04).
Discussion
Although patients with SLE and controls were from varied ethnic backgrounds, the frequency of white, Afro-European, and black people, and the frequency of HLA antigens in these ethnic groups did not differ significantly between patients and controls. This study showed that HLA-DR3 antigen was also increased in the total group of patients with SLE, in agreement with a previous study. '3 There are few studies correlating HLA antigens and clinical and laboratory defined subsets of SLE. In our series, the HLA-DR3 antigen conferred susceptibility to, whereas HLA-DR4 conferred protection against the development of NPSLE. As HLA-DR4 antigen has been previously associated with protection against the development of renal SLE,14 and most (85.7%) of our patients with NPSLE presented also nephritis, the question ofwhether renal SLE could act as a confounder should be considered. For our total group of patients, the frequency of HILA-DR4 antigen in patients with nephritis and controls (42-4% and 36-6% respectively) was not significantly different (uncorrected p = 046). In addition, HLA-DR4 frequency did not differ significantly (uncorrected p= 035) between patients with and without nephritis (42-4% and 33 3% respectively). For combinations of SLE subsets (presence or absence of neuropsychiatric or renal involvement), the comparisons of HLA-DR4 frequency among these subsets did not disclose any significant association. Therefore, in this study, the negative association between HLA-DR4 antigen and NPSLE was not influenced by concomitant renal SLE.
In the search for immunogenetic features which could confer susceptibility to NPSLE, we compared HLA frequencies between two subsets of patients with SLE (with or without neuropsychiatric involvement). Both diffuse and focal NPSLE were lumped together because some pathogenetic features described for diffuse disease have also been shown in focal disease.7 An increased frequency of HLA-DR9 and HLA-DQ2 antigens has not been previously reported in NPSLE. A previous study conducted on Japanese Few studies have investigated the presence of lymphocytotoxic antibodies bound to the lymphocytes of patients with SLE. '6 In this study, we investigated only warm reactive lymphocytotoxic antibodies (reactive at room temperature), and we did not separate lymphocyte subsets to verify specific cytotoxicity. Warm reactive lymphocytotoxic antibodies have been shown to be of the IgG class, they may produce lymphopenia directly or by means of the increased production of interferon--y, they seem to act like antinuclear antibodies, and have the highest toxicity in NPSLE. '6 In our series, lymphopenia occurred in 76-2% of patients with NPSLE and in 68-2% of patients with SLE without neuropsychiatric features. About 30% of patients with NPSLE and lymphopenia had lymphocytotoxic autoantibodies compared with only about 7% of lymphopenic patients without NPSLE. Although a direct association between lymphopenia and lymphocytotoxic antibodies would be expected, studies reported in the medical literature have not shown such association,16 suggesting that additional pathogenetic mechanisms may also be involved.
In conclusion, patients with NPSLE do have peculiar immunogenetic markers. HIA-DR3, HLA-DR9 and HLA-DQ2 antigens were associated with susceptibility, whereas HLA-DR4 was associated with protection against the development of NPSLE. We also showed an association between HLA-DR9 antigen and the presence of lymphocytotoxic autoantibody. Further studies of the nucleotide sequences which encode the antigen binding groove of candidate susceptibility and protective molecules may identify regions involved in the presentation of peptides derived from relevant autoantigens, and contribute to the understanding of the pathogenesis of SLE. 
